NUCLEUS NETWORK PTY LIMITED

Blackstone's Acquisition of I'rom Group Approved with Divestiture of CMAX Clinical Research

- The ACCC has approved Blackstone's acquisition of I'rom Group Co Limited, conditional on the divestiture of CMAX Clinical Research Pty Ltd. - This decision addresses concerns that the acquisition would consolidate phase 1 clinical trial services in Australia, potentially raising prices and reducing service quality. - The divestiture of CMAX to an ACCC-approved purchaser resolves competition issues related to both service provision and access to phase 1 clinical services. - Phase 1 clinical trials are crucial for testing the safety and tolerability of new therapeutic products, with Nucleus Network and CMAX being the largest suppliers in Australia.